# Fujian Shengdi Pharmaceutical Co., Ltd.: Phase 3 study closed enrollment, 144 enrolled (Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy |
| NCT ID | NCT06994650 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy |
| Intervention types | drug |
| Target enrollment | 144 |
| Site countries | China |
| Posted | 2025-05-29 |
| Planned start | 2025-08-13 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-04 |
| Last update posted | 2026-11-04 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 144 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06994650). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.